Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil.
Federal University of Pernambuco, Recife, Brazil.
Lett Appl Microbiol. 2022 Jul;75(1):45-50. doi: 10.1111/lam.13707. Epub 2022 Apr 4.
Purpureocillium lilacinum is a filamentous and hyaline fungus cosmopolitan, saprophytic, largely used in the biological control of plant-parasitic nematodes and insects, also considered an emerging and opportunistic human pathogen. The standard treatment for hyalohyphomycosis caused by P. lilacinum is not yet defined, since this fungus is resistant to different antifungals, in vitro and in vivo. The aim of this study was to evaluate and compare in vitro antifungal activity against environmental and clinical P. lilacinum isolates and our results demonstrated that these isolates can be resistant to newer generation triazoles, such as voriconazole, and to caspofungin, a drug of the echinocandin class. In summary, we highlight the importance of knowing the different susceptibility profiles of P. lilacinum isolates, and besides that, the emergence of uncommon human and animal opportunistic fungi, such P. lilacinum, especially during COVID-19, highlight the need for antifungal susceptibility testing of isolates since empirical therapy with different treatment schedules failed in great number of patients.
亮紫菌素是一种世界性的丝状和透明真菌，腐生，广泛用于防治植物寄生线虫和昆虫，也被认为是一种新出现的机会性病原体。由亮紫菌素引起的透明丝孢霉病的标准治疗方法尚未确定，因为这种真菌对不同的抗真菌药物具有体外和体内的耐药性。本研究旨在评估和比较环境和临床亮紫菌素分离株的体外抗真菌活性，我们的结果表明，这些分离株可能对新型唑类药物（如伏立康唑）和棘白菌素类药物（卡泊芬净）具有耐药性。总之，我们强调了了解亮紫菌素分离株不同药敏谱的重要性，此外，不常见的人和动物机会性真菌（如亮紫菌素）的出现，尤其是在 COVID-19 期间，突显了对分离株进行抗真菌药敏试验的必要性，因为不同治疗方案的经验性治疗在大量患者中失败。
